stockportfolio.pro
Stocks / CYTK vs MASI
CYTK vs MASI
Cytokinetics, Incorporated and Masimo Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cytokinetics, Incorporated (CYTK) | Masimo Corporation (MASI) | |
|---|---|---|
| Market cap | $9.1B | $9.4B |
| Revenue (latest FY) | $88.04M | $1.53B |
| Net income (latest FY) | $-784.96M | $-151.50M |
| Revenue growth (5y CAGR) | 9.5% | 5.9% |
| Net margin | -891.6% | -9.9% |
| Return on equity | 119.0% | -21.0% |
| P/E ratio | — | 44.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 8 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CYTK — free Open MASI — freeFrequently asked questions
Which is bigger, CYTK or MASI?
Masimo Corporation is larger by market capitalization — $9.4B versus $9.1B.
Which grows faster, CYTK or MASI?
Over the last five fiscal years, Cytokinetics, Incorporated grew revenue faster — 9.5%/yr versus 5.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.